Videos

The discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.

The discussion focuses on protocols for monitoring long-term complications from CAR T-cell and bispecific therapies, improving patient reintegration into community care posttreatment, and enhancing communication between academic and community oncologists.

Panelists discuss how patient selection for GPRC5D-targeted therapies in the relapsed/refractory setting is guided by factors such as prior treatment history, including the number and types of previous therapies, with special consideration given to patients who have exhausted other options or shown resistance to earlier lines of treatment.

Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

Panelists discuss disease-modifying biomarker data from the MANIFEST-2 study investigating pelabresib in myelofibrosis.

Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.

Panelists discuss the safety profile of the pelabresib and ruxolitinib combination in myelofibrosis.

Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.

Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.

Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.

Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.

Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.

Panelists discuss how amivantamab, FDA approved for first-line treatment of advanced non–small cell lung cancer with specific EGFR mutations, can lead to significant infusion-related reactions, including serious cases that may require dose adjustments or discontinuation.

Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), highlighting the efficacy of amivantamab-lazertinib over osimertinib, the importance of managing adverse events, adherence to National Comprehensive Cancer Network guidelines, and the need for patient engagement in treatment discussions to address unmet needs.

Uterine transposition is a newer tactic in the surgical oncology field to help preserve fertility for patients undergoing pelvic radiation.

Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.

Samantha Shenoy, NP, MSN, indicated that neurological issues were not prevalent with talquetamab, despite occurrences with other bispecifics antibodies.

Panelists discuss how GPRC5D bispecific therapies have shown promising efficacy in real-world relapsed/refractory multiple myeloma patients.

Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.

Mary Steinbach, APRN, shares her experience in managing dysgeusia and nail- and skin-related toxicities seen in patients with multiple myeloma who receive talquetamab.

Focusing on patients with multiple myeloma who receive GPRC5D-targeted therapy, Beth Faiman, CNP, PhD, discusses how long-term treatment impacts patients’ tolerance to adverse events.

Rafael Fonseca, MD, discusses the role of bispecifics in relapsed/refractory multiple myeloma and the implications of incorporating them into combination regimens.

Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.

Medical experts examine how overall survival data from KEYNOTE-564 has influenced the use of pembrolizumab as adjuvant therapy.

Medical experts discuss significant adverse effects of TKIs and IOs, including management and patient education, and highlight exciting pipeline therapies for non–clear cell RCC, such as Ipi + Nivo and zanzalintinib + Nivo.

The discussion examines whether the CAR T-cell referral process differs for in-state vs out-of-state patients, the role of social factors, and any changes or challenges in the referral process following recent CAR T approvals.

Medical experts discuss the CAR T-cell therapy referral process between community and academic centers, how academic centers can aid community oncologists in identifying eligible patients, determining suitable referrals, and managing patient expectations.

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.